Novel fibro-inflammatory biomarkers associated with disease activity in patients with Crohn’s disease

References

• Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5(5):484–498. DOI:10.1016/j.crohns.2011.07.003
   PubMed Web of Science ®Google Scholar
• Sostegni R, Daperno M, Scaglione N, et al. Review article: crohn’s disease: monitoring disease activity. Alimentary Pharmacol and Therapeutics, Supplement. 2003;17:11–17.
   PubMed Web of Science ®Google Scholar
• Bruining DH, Zimmermann EM, Loftus EVJ, et al. Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel crohn’s disease. Radiology. 2018;286(3):776–799. DOI:10.1148/radiol.2018171737
   PubMed Web of Science ®Google Scholar
• Lin S-N, Musso A, Wang J, et al. Human intestinal myofibroblasts deposited collagen VI enhances adhesiveness for T cells - a novel mechanism for maintenance of intestinal inflammation. Matrix Biol. 2022;113:1–21.
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Lindholm M, Langholm LL, et al. The intestinal tissue homeostasis–the role of extracellular matrix remodeling in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol Taylor & Francis. 2019;13(10):977–993. DOI:10.1080/17474124.2019.1673729
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Bay-Jensen AC, Leeming DJ, et al. Quantification of “end products” of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways – implications for modern clinical chemistry. Biomarkers. 2013;18(5):375–378. DOI:10.3109/1354750X.2013.789084
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Henriksen K, Leeming DJ, et al. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease? Clin Biochem. 2010;43(10–11):793–804. DOI:10.1016/j.clinbiochem.2010.03.015
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Nielsen SH, Leeming DJ, et al. The good and the bad collagens of fibrosis – their role in signaling and organ function. Adv Drug Deliv Rev. 2017;121:43–56.
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Godskesen LE, Jensen MD, et al. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen are novel serological biomarkers to differentiate Crohn’s disease from ulcerative colitis. J Crohns Colitis. 2015;9(10):863–872. DOI:10.1093/ecco-jcc/jjv123
   PubMed Web of Science ®Google Scholar
• van Haaften WT, Mortensen JH, Karsdal MA, et al. Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease. Aliment Pharmacol Ther. 2017;46(1):26–39. DOI:10.1111/apt.14092
   PubMed Web of Science ®Google Scholar
• Bourgonje AR, Alexdottir MS, Otten AT, et al. Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease. Aliment Pharmacol Ther. 2022;56(4):675–693. DOI:10.1111/apt.17063
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Maxwell L, Doe W. Inflammation Location, but Not Type, Determines the Increase in TGF-β1 and IGF-1 Expression and Collagen Deposition in IBD Intestine. Inflamm Bowel Dis. 2001;7(1):16–26.
   PubMed Web of Science ®Google Scholar
• Rieder F, Fiocchi C. Mechanisms of tissue remodeling in inflammatory bowel disease. Dig Dis. 2013;31(2):186–193.
   PubMed Web of Science ®Google Scholar
• Latella G, Di Gregorio J, Flati V, et al. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand J Gastroenterol. 2014;50(1):53–65. DOI:10.3109/00365521.2014.968863
   Web of Science ®Google Scholar
• Rieder F, Fiocchi C, Rogler G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):340–350.e6.
   PubMed Web of Science ®Google Scholar
• Pehrsson M, Mortensen JH, Manon-Jensen T, et al. Enzymatic cross-linking of collagens in organ fibrosis – resolution and assessment. Expert Rev Mol Diagn. 2021;00:1–16.
   Google Scholar
• Wagatsuma K, Yokoyama Y, Nakase H. Role of biomarkers in the diagnosis and treatment of inflammatory bowel disease. Life. 2021;11(12):1375.
   PubMedGoogle Scholar
• State M, Negreanu L, Voiosu T, et al. Surrogate markers of mucosal healing in inflammatory bowel disease: a systematic review. World J Gastroenterol. 2021;27(16):1828–1840. DOI:10.3748/wjg.v27.i16.1828
   PubMed Web of Science ®Google Scholar
• Chen R, Zheng J, Li L, et al. Metabolomics facilitate the personalized management in inflammatory bowel disease. Therap Adv Gastroenterol. 2021;14:175628482110644.
   Web of Science ®Google Scholar
• Alghoul Z, Yang C, Merlin D. The current status of molecular biomarkers for inflammatory bowel disease. Biomedicines. 2022;10(7):1492.
   PubMed Web of Science ®Google Scholar
• Krzystek-Korpacka M, Kempiński R, Bromke M, et al. Biochemical biomarkers of mucosal healing for inflammatory bowel disease in adults. Diagnostics. 2020;10(6):367. DOI:10.3390/diagnostics10060367
   Web of Science ®Google Scholar
• Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease. Digestion. 2023;104(1):30–41.
   PubMed Web of Science ®Google Scholar
• Elhag DA, Kumar M, Saadaoui M, et al. Inflammatory bowel disease treatments and predictive biomarkers of therapeutic response. Int J Mol Sci. 2022;23(13):6966. DOI:10.3390/ijms23136966
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Microbiome-based biomarkers for IBD. Inflamm Bowel Dis. 2020;26(10):1463–1469.
   PubMed Web of Science ®Google Scholar
• Guo X, Huang C, Xu J, et al. Gut microbiota is a potential biomarker in inflammatory bowel disease. Front Nutr Frontiers Media SA. 2022;8. DOI:10.3389/fnut.2021.818902
   Google Scholar
• Agrawal M, Colombel J-F. Treat-to-target in inflammatory bowel diseases, what is the target and how do we treat? Gastrointest Endosc Clin N Am. 2019;29(3):421–436.
   PubMedGoogle Scholar
• Plevris N, Lees CW. Disease monitoring in inflammatory bowel disease: evolving principles and possibilities. Gastroenterology. 2022;162(5):1456–1475.e1. InternetAvailable from. DOI:10.1053/j.gastro.2022.01.024
   PubMed Web of Science ®Google Scholar
• Mazzuoli S, Guglielmi FW, Antonelli E, et al. Definition and evaluation of mucosal healing in clinical practice. Digestive Liver Dis. 2013;45(12):969–977. InternetAvailable from. DOI:10.1016/j.dld.2013.06.010
   Web of Science ®Google Scholar
• Krzystek-Korpacka M, Kempiński R, Bromke M, et al. Biochemical biomarkers of mucosal healing for inflammatory bowel disease in adults. Diagnostics. 2020;10(6):1–31. DOI:10.3390/diagnostics10060367
   Web of Science ®Google Scholar
• Shah SC, Colombel J-F, Sands BE, et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016;43(3):317–333. DOI:10.1111/apt.13475
   PubMed Web of Science ®Google Scholar
• Reinink AR, Lee TC, Higgins PDR. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis. 2016;22(8):1859–1869.
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512. DOI:10.1016/S0016-5107(04)01878-4
   PubMed Web of Science ®Google Scholar
• Christensen B, Erlich J, Gibson PR, et al. Histologic healing is more strongly associated with clinical outcomes in ileal crohn’s disease than endoscopic healing. Clin Gastroenterol Hepatol. 2020;18(11):2518–2525.e1. DOI:10.1016/j.cgh.2019.11.056
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15(9):1295–1301. DOI:10.1002/ibd.20927
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining Therapeutic Goals for Treat-to-Target. Official Journal of the American College of Gastroenterology | ACG. 2015;110(9) :1324–1338.
   PubMed Web of Science ®Google Scholar
• Lafeuille P, Hordonneau C, Vignette J, et al. Sa465 Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2021;53(6):577–586. DOI:10.1016/S0016-5085(21)01921-1
   PubMedGoogle Scholar
• Bettenworth D, Bokemeyer A, Baker M, et al. Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut. 2019;68(6):1115–1126. DOI:10.1136/gutjnl-2018-318081
   PubMed Web of Science ®Google Scholar
• McCurdy JD, Enders FT, Jones A, et al. Detection of cytomegalovirus in patients with inflammatory bowel disease: where to biopsy and how many biopsies? Inflamm Bowel Dis. 2015;21(12):2833–2838. DOI:10.1097/MIB.0000000000000556
   PubMed Web of Science ®Google Scholar
• Langner C, Magro F, Driessen A, et al. The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch. 2014;464:511–527.
   PubMed Web of Science ®Google Scholar
• Henriksen K, Leeming DJ, Byrjalsen I, et al. Osteoclasts prefer aged bone. Osteoporos Int. 2007;18:751–759.
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Nielsen MJ, Dai Y, et al. Enzyme-linked immunosorbent serum assay specific for the 7S domain of Collagen Type IV (P4NP 7S): a marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol Res. 2012;42(5):482–493. DOI:10.1111/j.1872-034X.2011.00946.x
   PubMed Web of Science ®Google Scholar
• Nielsen MJ, Nedergaard AF, Sun S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5(3):303–315. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/23634241
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Sinkeviciute D, Manon-Jensen T, et al. A specific calprotectin neo-epitope (CPa9-HNE) in serum from inflammatory bowel disease patients is associated with neutrophil activity and endoscopic severity. J Crohns Colitis [Internet]. 2022; Available from: http://www.ncbi.nlm.nih.gov/pubmed/35304895
   Google Scholar
• Barascuk N, Veidal SS, Larsen L, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43(10–11):899–904. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/20380828
   PubMed Web of Science ®Google Scholar
• Sand JM, Larsen L, Hogaboam C, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis–validation of two novel biomarker assays. PLoS ONE. 2013;8:e84934. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/24376856
   PubMed Web of Science ®Google Scholar
• Pehrsson M, Manon-Jensen T, Sun S, et al. An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution. Liver Int. 2022;42(7):1605–1617. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/35384259
   PubMed Web of Science ®Google Scholar
• Bin CH, Hao B, Sun J, et al. C-Terminal cross-linked telopeptides of type ii collagen as biomarker for radiological knee osteoarthritis: a meta-analysis. Cartilage. 2020;11:512–520.
   PubMed Web of Science ®Google Scholar
• Cloos PA, Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem J. 2000;345(Pt 3):473–480. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/10642504
   PubMedGoogle Scholar
• Vassiliadis E, Oliveira CP, Alvares-da-Silva MR, et al. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res. 2012;4(4):403–414. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/23145208
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Genovese F, Rasmussen DGK, et al. Considerations for understanding protein measurements: identification of formation, degradation and more pathological relevant epitopes. Clin Biochem. 2021;97:11–24. InternetAvailable from. DOI:10.1016/j.clinbiochem.2021.08.007
   PubMed Web of Science ®Google Scholar
• Leeming DJ, He Y, Veidal SS, et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 2011;16(7):616–628. DOI:10.3109/1354750X.2011.620628
   PubMed Web of Science ®Google Scholar
• Veidal SS, Karsdal MA, Vassiliadis E, et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis–identification and validation of a novel biochemical marker assay. PLoS ONE. 2011;6(9):e24753. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/21935455
   PubMed Web of Science ®Google Scholar
• Gudmann NS, Manon-Jensen T, Sand JMB, et al. Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease. Biochem Biophys Res Commun. 2018;503(3):1284–1290. InternetAvailable from: https://www.sciencedirect.com/science/article/pii/S0006291X1831533X
   PubMed Web of Science ®Google Scholar
• Vassiliadis E, Veidal SS, Simonsen H, et al. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers. 2011;16(5):426–433. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/21612338
   PubMed Web of Science ®Google Scholar
• Sand JMB, Knox AJ, Lange P, et al. Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res. 2015;16(1).
   PubMedGoogle Scholar
• Nissen NI, Kehlet S, Johansen AZ, et al. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenocarcinoma. Int J Cancer. 2021;149(1):228–238. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/33687786
   PubMed Web of Science ®Google Scholar
• Madsen EA, Thorlacius-Ussing J, Nissen NI, et al. Type XXII collagen complements fibrillar collagens in the serological assessment of tumor fibrosis and the outcome in pancreatic cancer. Cells. 2022;11(23):11. DOI:10.3390/cells11233763
   Web of Science ®Google Scholar
• Veidal SS, Karsdal MA, Nawrocki A, et al. Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair. 2011;4(1):22. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/21970406
   PubMedGoogle Scholar
• Vassiliadis E, Larsen DV, Clausen RE, et al. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomark Insights. 2011;6:49–58. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/21499440
   PubMedGoogle Scholar
• Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11246–11259.
   PubMed Web of Science ®Google Scholar
• Kiss LS, Papp M, Lovasz BD, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification? Inflamm Bowel Dis. 2012;18(9):1647–1654. DOI:10.1002/ibd.21933
   PubMed Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518–1523. DOI:10.1136/gut.2007.146357
   PubMed Web of Science ®Google Scholar
• Lynn AM, Jr EVL. Luminal Crohn’s Disease: biomarkers in Inflammatory Bowel Diseases. Ding NS, Cruz P De editors. Cham, Switzerland: Springer Nature Switzerland; 2019.
   Google Scholar
• Mumolo MG, Bertani L, Ceccarelli L, et al. From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol. 2018;24:3681–3694.
   PubMed Web of Science ®Google Scholar
• Pehrsson M, Mortensen JH, Manon-Jensen T, et al. Enzymatic cross-linking of collagens in organ fibrosis–resolution and assessment. Expert Rev Mol Diagn. 2021;21:1049–1064. InternetAvailable from. DOI:10.1080/14737159.2021.1962711
   PubMed Web of Science ®Google Scholar
• Hansen JF, Juul Nielsen M, Nyström K, et al. PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. Scand J Gastroenterol. 2018;53(1):83–87. InternetAvailable from. DOI:10.1080/00365521.2017.1392596
   PubMed Web of Science ®Google Scholar
• Luo Y, Oseini A, Gagnon R, et al. An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis. Sci Rep. 2018;8:1–9. InternetAvailable from. DOI:10.1038/s41598-018-30457-y
   PubMed Web of Science ®Google Scholar
• Jessen H, Hoyer N, Prior TS, et al. Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis. BMC Pulm Med. 2021;21(1):382. DOI:10.1186/s12890-021-01684-3
   PubMed Web of Science ®Google Scholar
• Jessen H, Hoyer N, Prior TS, et al. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respir Res. 2021;22:205.
   PubMed Web of Science ®Google Scholar
• Alexdottir MS, Bourgonje AR, Karsdal MA, et al. Serological biomarkers of extracellular matrix turnover and neutrophil activity are associated with long-term use of vedolizumab in patients with crohn’s disease. Int J Mol Sci. 2022;23(15):i468–469. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/35897710
   Web of Science ®Google Scholar
• Alexdottir MS, Bourgonje AR, Karsdal MA, et al. Serological biomarkers of intestinal collagen turnover identify early response to infliximab therapy in patients with crohn’s disease. Front Med. 2022;9. DOI:10.3389/fmed.2022.933872
   Web of Science ®Google Scholar
• Mortensen J, Feagan B, Bay-Jensen AC, et al. P516 Serological biomarkers of tissue remodeling are associated with endoscopic remission in Crohn’s disease patients treated with GED-0301 (mongersen). J Crohns Colitis. 2021;15(Supplement_1):S494–495. DOI:10.1093/ecco-jcc/jjab076.638
   Google Scholar
• Domislovic V, Høg Mortensen J, Lindholm M, et al. Inflammatory biomarkers of extracellular matrix remodeling and disease activity in crohn’s disease and ulcerative colitis. J Clin Med. 2022;11(19):11. DOI:10.3390/jcm11195907
   Web of Science ®Google Scholar
• Goffin L, Fagagnini S, Vicari A, et al. Anti-MMP-9 antibody: a promising therapeutic strategy for treatment of inflammatory bowel disease complications with fibrosis. Inflamm Bowel Dis. 2016;22(9):2041–2057. DOI:10.1097/MIB.0000000000000863
   PubMed Web of Science ®Google Scholar
• van Haaften WT, Mortensen JH, Dige AK, et al. Serological biomarkers of tissue turnover identify responders to anti-tnf therapy in Crohn’s disease: a pilot study. Clin Transl Gastroenterol. 2020;11(9):e00217. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/33094957
   PubMed Web of Science ®Google Scholar
• Lindholm M, Manon-Jensen T, Madsen GI, et al. Extracellular matrix fragments of the basement membrane and the interstitial matrix are serological markers of intestinal tissue remodeling and disease activity in dextran sulfate sodium colitis. Dig Dis Sci. 2019;64(11):3134–3142. DOI:10.1007/s10620-019-05676-6
   PubMed Web of Science ®Google Scholar
• Lindholm M, Godskesen LE, Manon-Jensen T, et al. Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD. Sci Rep. 2021;11(1):14713. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/34282237
   PubMed Web of Science ®Google Scholar
• Mortensen JH, van Haaften WT, Karsdal MA, et al. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn’s Disease. J Clin Gastroenterol. 2021;55(1):59–66. DOI:10.1097/MCG.0000000000001341
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Manon-Jensen T, Jensen MD, et al. Ulcerative colitis, Crohn’s disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn’s disease. PLoS ONE. 2017;12(10):1–16. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/29028807
   Web of Science ®Google Scholar
• Mortensen J, Focht G, Pehrsson M, et al. P204 Endotrophin (PRO-C6) is associated with MRE confirmed intestinal strictures and Protein FingerPrint biomarkers of collagen degradation is associated with ulcerations in paediatric Crohn’s disease patients – results from the ImageKids study. J Crohns Colitis. 2022;16(Supplement_1):i264–265. InternetAvailable from: https://academic.oup.com/ecco-jcc/article/16/Supplement_1/i264/6512851
   Google Scholar
• Karsdal MA, Leeming DJ, Henriksen K, et al., editors. Biochemistry of collagens, laminins and elastin: structure, function and biomarkers. 2nd ed. London, UK: Elsevier Inc.; 2019.
   Google Scholar
• Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease. Gut. 2004;53(5):701–709. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/15082589
   PubMed Web of Science ®Google Scholar
• Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw index. Inflamm Bowel Dis. 2006;12(4):304–310. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/16633052
   PubMed Web of Science ®Google Scholar
• Koutroumpakis E, Katsanos KH. Implementation of the simple endoscopic activity score in Crohn’s disease. Saudi J Gastroenterol. 2016;22(3):183–191.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Nuutinen H, Turunen U, et al. Endoscopic evaluation of Crohn's disease activity. Inflamm Bowel Dis. 2010;16(12):2131–2136. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/20848462
   PubMed Web of Science ®Google Scholar
• Nanni P, Parisi D, Roda G, et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom. 2007;21(24):4142–4148. DOI:10.1002/rcm.3323
   PubMed Web of Science ®Google Scholar
• Wik L, Nordberg N, Broberg J, et al. Proximity extension assay in combination with next- generation sequencing for high-throughput proteome-wide analysis authors proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis. Mol & Cell Proteomics. 2021;20:100168.
   PubMedGoogle Scholar
• Gold L, Ayers D, Bertino J, et al. Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. PLoS ONE. 2010;5(12):e15004. DOI:10.1371/journal.pone.0015004
   PubMed Web of Science ®Google Scholar
• Heier CR, Fiorillo AA, Chaisson E, et al. Identification of pathway-specific serum biomarkers of response to glucocorticoid and infliximab treatment in children with inflammatory bowel disease. Nat Publishing Group. 2016;7(9):1–8. DOI:10.1038/ctg.2016.49
   Google Scholar
• Kalla R, Adams AT, Bergemalm D, et al. Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. J Crohns Colitis. 2020;1:1–10.
   Google Scholar
• Soomro S, Venkateswaran S, Vanarsa K, et al. Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen. Nat Commun. 2021;12(1):1–11. DOI:10.1038/s41467-021-24235-0
   PubMed Web of Science ®Google Scholar
• Pierre N, Huynh-Thu VA, Marichal T, et al. Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn’s disease stopping infliximab: when the remission state hides different types of residual disease activity. Gut. 2023;72(3):443–450. 2022;gutjnl-2022-327321. DOI:10.1136/gutjnl-2022-327321
   PubMed Web of Science ®Google Scholar
• Leptak C, Menetski JP, Wagner JA, et al. What evidence do we need for biomarker qualification? Sci, trans med. 2017;9(417):1–5. DOI:10.1126/scitranslmed.aal4599
   Web of Science ®Google Scholar
• Dingare C, Niedzwetzki A, Klemmt PA. The Hippo pathway effector Taz is required for cell morphogenesis and fertilization in zebrafish. Pathways for Bio Integration in Drug Develop. 2018;145(22). DOI:10.1242/dev.167023
   Google Scholar
• Rasmussen DGK, Anstee QM, Torstenson R, et al. NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned. J Hepatol. 2022;78(4):852–865. DOI:10.1016/j.jhep.2022.11.028
   PubMedGoogle Scholar
• Honig G, Heller C, Hurtado-Lorenzo A. Defining the path forward for biomarkers to address unmet needs in inflammatory bowel diseases. Inflamm Bowel Dis. 2020;26(10):1451–1462.
   PubMed Web of Science ®Google Scholar
• FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. US Food and Drug Administration Web Site. 2021. https://www.ncbi.nlm.nih.gov/books/NBK338449/
   Google Scholar
• Masucci GV, Cesano A, Hawtin R, et al. Validation of biomarkers to predict response to immunotherapy in cancer: volume I — pre-analytical and analytical validation. J Immunother Cancer. 2016;4(1):1–25. DOI:10.1186/s40425-016-0178-1
   Google Scholar
• Dobbin KK, Cesano A, Alvarez J, et al. Validation of biomarkers to predict response to immunotherapy in cancer: volume II — clinical validation and regulatory considerations. J Immunother Cancer. 2016;4(1):1–14. DOI:10.1186/s40425-016-0179-0
   Google Scholar
• U.S Food & Drug Administration: center for Drug Evaluation and Research. More About Biomarkers & Qualification. 2021. https://www.fda.gov/drugs/biomarker-qualification-program/more-about-biomarkers-qualification
   Google Scholar
• Dulai PS, Peyrin-Biroulet L, Danese S, et al. Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases. Gastroenterology. 2019;157(4):1032–1043.e1. DOI:10.1053/j.gastro.2019.06.018
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Kraus VB, Shevell D, et al. Profiling and targeting connective tissue remodeling in autoimmunity - a novel paradigm for diagnosing and treating chronic diseases. Autoimmun Rev. 2020;20(1):102706. DOI:10.1016/j.autrev.2020.102706
   PubMed Web of Science ®Google Scholar